Although Reduvo approval is very important but QIXLEEF interim reports are ultimately is big one. It will also what will initiate big pharma move toward tetra imo. The pain industry is huge and this really has the potential for big change.
Below are the major milestones expected this Q. It looks that their hands are full. 1. Reduvo DIN. Big item it will make tetra revenue generating pharma. Expected anytime in Q4
comment from ma&d
"The Company began pre-launch activities for its REDUVOTM drug candidate and expects to expand these activities over the coming months. The review of the New Drug Submission entered the Scientific Review stage after successful completion of the screening phase and the issuance of the DEL-sale and distribution, the final stage of drug approval. Only minor changes (e.g., font size) were required as part of the label review"
2. QIXLEEF reborn1 interim results report. This is very important. Although recent highlighted positive results but this will discuss details. Note that Tbp will market QIXLEEF based on reborn 1 based on latest info and won't wait for reborn 2. Check the details on news release of using fast track path. Note also another site was added late august so we have two sites now.
3. QIXLEEF plenitude interim report. These results will be required for the fast track fda approval.
4. QIXLEEF EU approval for orphan drug is expected after 30 days based on last week NR.
5. CAMUZ advancing bridging between CAMUZ and QIXLEEF.
6. ARD003 start phase 1 this is pending funding planned at us Canada India and Brazil
There are more listed in the latest management discussions but I presented the big one only
good luck guys